 FSD Pharma Inc said it has entered into an agreement with Covar Pharmaceuticals Inc, a contract development and manufacturing services organization, to start work on providing research quantities of its drug candidate, Lucid-PSYCH, on an exclusive basis for further clinical evaluation. FSD has selected Lucid-PSYCH formerly Lucid-201, a psychoactive compound, to advance its research into the treatment of major depressive disorders based on analysis of the drug candidates pharmaceutical and metabolic properties processed via machine learning algorithms, as well as for its potential proprietary position. 